|
|
|
| Dec. 19, 2012 |
Amgen Finalizes Agreement Resolving Previously Announced Federal Investigations
|
| Dec. 13, 2012 |
Amgen Announces Appointment of Robert A. Eckert to Board of Directors
|
| Dec. 13, 2012 |
Amgen Names Robert A. Bradway Chairman of the Board Of Directors
|
| Dec. 13, 2012 |
Amgen Announces 31 Percent Increase In 2013 First Quarter Dividend And Increase In Its Share Repurchase Authorization
|
| Dec. 10, 2012 |
Amgen to Acquire deCODE Genetics, a Global Leader in Human Genetics
|
| Dec. 5, 2012 |
Amgen Highlights Data To Be Presented At American Society of Hematology Annual Meeting
|
| Nov. 20, 2012 |
Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
|
| Nov. 12, 2012 |
Amgen and Pfizer Highlight Data to be Presented at American College of Rheumatology Meeting
|
| Nov. 6, 2012 |
The Lancet Publication Of LAPLACE-TIMI 57 And MENDEL Studies Showed AMG 145 Significantly Reduced LDL Cholesterol
|
| Nov. 5, 2012 |
Circulation Publishes Results From RUTHERFORD Study Which Showed AMG 145 Significantly Reduced LDL Cholesterol In Patients With Heterozygous Familial Hypercholesterolemia
|
| Nov. 5, 2012 |
Journal of the American Medical Association Publishes AMG 145 Phase 2 GAUSS Study Showing Significant Reductions In LDL Cholesterol In Statin-Intolerant Patients
|
| Nov. 3, 2012 |
Phase 3 Sensipar®/Mimpara® EVOLVE(TM) Trial Published In The New England Journal Of Medicine
|
| Nov. 2, 2012 |
Amgen To Present Data From Four Phase 2 Studies At Upcoming American Heart Association Scientific Sessions 2012
|
| Nov. 1, 2012 |
Amgen To Webcast Investor Meeting At Upcoming American Heart Association Scientific Sessions 2012
|
| Oct. 23, 2012 |
Amgen's Third Quarter 2012 Revenues Increased 10 Percent To $4.3 Billion And Adjusted Earnings Per Share (EPS) Increased 19 Percent To $1.67
|
| Oct. 18, 2012 |
Amgen Announces Webcast of 2012 Third Quarter Financial Results
|
| Oct. 14, 2012 |
Amgen Presents Several Sub-Analyses At ASBMR From The Ongoing Open-Label Extension Study Of The Pivotal Phase 3 Prolia Fracture Trial
|
| Oct. 12, 2012 |
Amgen Appoints Cynthia Patton Senior Vice President And Chief Compliance Officer
|
| Oct. 11, 2012 |
Amgen Announces 2012 Fourth Quarter Dividend
|
| Sep. 20, 2012 |
FDA Approves New Indication For Prolia® (Denosumab) For The Treatment Of Bone Loss In Men With Osteoporosis At High Risk For Fracture
|
| Sep. 10, 2012 |
Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
|
| Sep. 10, 2012 |
Amgen To Present At The Bank of America Merrill Lynch Global Healthcare Conference
|
| Sep. 7, 2012 |
Amgen To Present At The Morgan Stanley Global Healthcare Conference
|
| Aug. 31, 2012 |
Amgen To Present At The Baird Healthcare Conference
|
| Aug. 8, 2012 |
Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
|
| Jul. 26, 2012 |
Amgen's Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83
|
| Jul. 23, 2012 |
Amgen Announces Webcast of 2012 Second Quarter Financial Results
|
| Jul. 19, 2012 |
Amgen Announces 2012 Third Quarter Dividend
|
| Jul. 5, 2012 |
Amgen Completes Acquisition of KAI Pharmaceuticals
|
| Jun. 25, 2012 |
Actress Maura Tierney And Amgen Launch The Chemotherapy: Myths or Facts (TM) Campaign
|
| Jun. 12, 2012 |
Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
|
| Jun. 11, 2012 |
20th Annual Amgen Award For Science Teaching Excellence Honors Nine Outstanding Teachers
|
| Jun. 8, 2012 |
Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE(TM) Trial
|
| May. 16, 2012 |
Amgen's BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate Of Complete Response In Adult Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia
|
| May. 16, 2012 |
Analysis Of Rilotumumab (AMG 102) Data Identifies A Potential Predictive Biomarker For Patients With Gastric Or Gastroesophageal Cancer
|
| May. 11, 2012 |
Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars
|
| May. 9, 2012 |
Cancer Support Community Launches National Program to Assist Patients With Cancer, Make Informed Decisions About Care
|
| May. 4, 2012 |
Amgen to Present at the Baird Growth Stock Conference
|
| May. 3, 2012 |
Amgen to Present at the Deutsche Bank 37th Annual Healthcare Conference
|
| May. 3, 2012 |
CURE Magazine Announces Winner of the 2012 Extraordinary Healer Award for Oncology Nursing
|
| May. 1, 2012 |
Four Californians Selected As Breakaway from Cancer® Champions To Be Honored During Amgen Tour of California
|
| Apr. 26, 2012 |
Amgen Receives Complete Response Letter From FDA for XGEVA® sBLA for Prevention of Bone Metastases
|
| Apr. 25, 2012 |
Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
|
| Apr. 24, 2012 |
Amgen's First Quarter 2012 Revenue Increased 9 Percent To $4.0 Billion And Adjusted Earnings Per Share (EPS) Increased 20 Percent To $1.61
|
| Apr. 23, 2012 |
A Tribute to George Rathmann, Amgen's Founding CEO (1927-2012)
|
| Apr. 19, 2012 |
Amgen Announces Webcast of 2012 First Quarter Financial Results
|
| Apr. 10, 2012 |
Amgen to Acquire Privately Held KAI Pharmaceuticals
|
| Apr. 4, 2012 |
UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis
|
| Apr. 2, 2012 |
Amgen and AstraZeneca Announce Collaboration to Jointly Develop and Commercialize Clinical-Stage Inflammation Portfolio
|
| Mar. 28, 2012 |
Amgen Announces Phase 2 Study Results for Brodalumab in Moderate to Severe Plaque Psoriasis Published in the New England Journal of Medicine
|
| Mar. 25, 2012 |
Amgen's PCSK9 Inhibitor Reduced LDL Cholesterol up to 81 Percent in Phase 1b Study
|
| Mar. 15, 2012 |
Amgen Announces 2012 Second Quarter Dividend
|
| Mar. 7, 2012 |
Amgen Completes Tender Offer for Outstanding Shares of Micromet, Inc.
|
| Mar. 6, 2012 |
Schwartz Center Receives $500,000 Grant from the Amgen Foundation
|
| Mar. 2, 2012 |
Amgen Announces Initial Results of Tender Offer for Outstanding Shares of Micromet, Inc. and Commencement of Subsequent Offering Period
|
| Feb. 29, 2012 |
Amgen to Present at the Cowen and Company 32nd Annual Healthcare Conference
|
| Feb. 28, 2012 |
Amgen and European Schoolnet Launch New Professional Development Initiative for Life Science Teachers
|
| Feb. 23, 2012 |
Amgen to Present at the Citi 2012 Global Healthcare Conference
|
| Feb. 21, 2012 |
CURE Magazine Teams up with Amgen Oncology and Breakaway from Cancer® to Launch 2012 Extraordinary Healer Award for Oncology Nursing
|
| Feb. 15, 2012 |
Amgen and Micromet Announce Early Termination of HSR Waiting Period for Amgen's Acquisition of Micromet
|
| Feb. 14, 2012 |
Amgen Names Michael Severino, M.D., Senior Vice President, Global Development and Corporate Chief Medical Officer
|
| Feb. 13, 2012 |
Amgen to Present at the Leerink Swann Global Healthcare Conference
|
| Feb. 8, 2012 |
Amgen to Discuss Application for New Use of XGEVA® (denosumab) at FDA Oncologic Drugs Advisory Committee Meeting
|
| Jan. 26, 2012 |
Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion and Adjusted Earnings Per Share (EPS) Increased 2 Percent to $5.33
|
| Jan. 26, 2012 |
Amgen to Acquire Micromet
|
| Jan. 24, 2012 |
Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
|
| Jan. 4, 2012 |
Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
|
|
|
|
|
|
|
|
|
|
|
|
